Kathryn Hunter

709 total citations
8 papers, 246 citations indexed

About

Kathryn Hunter is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kathryn Hunter has authored 8 papers receiving a total of 246 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Kathryn Hunter's work include Angiogenesis and VEGF in Cancer (5 papers), Cancer Treatment and Pharmacology (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Kathryn Hunter is often cited by papers focused on Angiogenesis and VEGF in Cancer (5 papers), Cancer Treatment and Pharmacology (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Kathryn Hunter collaborates with scholars based in United States and France. Kathryn Hunter's co-authors include Susan Jones‐Bolin, Hugh Zhao, Bruce Ruggeri, Hong Chang, Candy Robinson, Paweł Dobrzański, Andres J. Klein–Szanto, Lisa D. Aimone, Thelma S. Angeles and Ted L. Underiner and has published in prestigious journals such as Cancer Research, Journal of Virology and Journal of Medicinal Chemistry.

In The Last Decade

Kathryn Hunter

6 papers receiving 238 citations

Peers

Kathryn Hunter

MB

CMN

ONCOL

CB

CR

Ashley Jarvis United Kingdom

Sara Charmsaz Ireland

Katherine Amato United States

Valentina Fodale Italy

Jessica Lisle Australia

Kevin Lou United States

Hyun‐Jung Byun South Korea

Jason B. Mullenix United States

Mina Aikawa United States

Jaya Iyer United States

Ashley Jarvis United Kingdom

Kathryn Hunter

295 ×1.6

MB

163 ×1.6

CMN

122 ×1.8

ONCOL

64 ×1.3

CB

63 ×1.9

CR

Citations per year, relative to Kathryn Hunter Kathryn Hunter (= 1×) peers Ashley Jarvis

Countries citing papers authored by Kathryn Hunter

Since Specialization

Citations

This map shows the geographic impact of Kathryn Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Hunter more than expected).

Fields of papers citing papers by Kathryn Hunter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Hunter. The network helps show where Kathryn Hunter may publish in the future.

Co-authorship network of co-authors of Kathryn Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn Hunter. A scholar is included among the top collaborators of Kathryn Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn Hunter. Kathryn Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Sanchez, Eric, Mingjie Li, Jennifer Li, et al.. (2012). CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leukemia Research. 36(11). 1422–1427. 19 indexed citations

2.

Hudkins, Robert L., Allison L. Zulli, Ted L. Underiner, et al.. (2011). Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent. Journal of Medicinal Chemistry. 55(2). 903–913. 38 indexed citations

3.

Underiner, Ted L., Bruce Ruggeri, Lisa D. Aimone, et al.. (2008). TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs. Bioorganic & Medicinal Chemistry Letters. 18(7). 2368–2372. 8 indexed citations

4.

Ruggeri, Bruce, Ted L. Underiner, Diane E. Gingrich, et al.. (2007). CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models. Molecular Cancer Therapeutics. 6. 2 indexed citations

5.

Jones‐Bolin, Susan, Hugh Zhao, Kathryn Hunter, Andres J. Klein–Szanto, & Bruce Ruggeri. (2006). The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Molecular Cancer Therapeutics. 5(7). 1744–1753. 38 indexed citations

6.

Jones‐Bolin, Susan, Kathryn Hunter, Hugh Zhao, Andres J. Klein–Szanto, & Bruce Ruggeri. (2005). Trk inhibitors provide better efficacy than a VEGF-R kinase inhibitor in combination with gemcitabine on improving survival in an orthotopic model of human PDAC. Cancer Research. 65. 711–712. 1 indexed citations

7.

Dobrzański, Paweł, Kathryn Hunter, Susan Jones‐Bolin, et al.. (2004). Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist. Cancer Research. 64(3). 910–919. 139 indexed citations

8.

Panoutsakopoulou, Vily, et al.. (1999). Genetic Regulation of Long-Term Nonprogression in E-55+ Murine Leukemia Virus Infection in Mice. Journal of Virology. 73(11). 9232–9236. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact